Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer

Submitted: 24 May 2012
Accepted: 26 July 2012
Published: 30 November 2012
Abstract Views: 1145
PDF: 480
HTML: 498
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Ubiquitin-specific protease 22 (USP22), a novel ubiquitin hydrolase, has been implicated in oncogenesis and cancer progression in various types of human cancer. However, the clinical significance of USP22 expression in non-small cell lung cancer (NSCLC) has not been determined. In the present study, USP22 messenger RNA (mRNA) and protein levels were analyzed by quantitative real-time polymerase chain reaction (PCR) and western blot analysis in 30 cases of NSCLC and in corresponding non-tumor tissue samples. Furthermore, immunohistochemistry was performed to detect USP22 protein expression in 86 primary tumor tissues derived from clinically annotated NSCLC cases at stage I-II. In our analysis we found that both USP22 mRNA and protein levels in NSCLC tissues were significantly higher than those in corresponding non-tumor tissues and that there was a significant correlation between the expression of USP22 mRNA and protein (P=0.000, κ=0.732). In addition, a high-level of USP22 expression was observed in 53.3% (39 out of 86) cases and it was correlated with large tumor size (P=0.029) and lymph node metastasis (P=0.026). Patients with tumors displaying a high-level of USP22 expression showed significantly shorter survival (P=0.006, log-rank test). Importantly, multivariate analysis showed that high USP22 protein expression was an independent prognostic factor for NSCLC patients (P=0.003). In sum, our data suggest that USP22 plays an important role in NSCLC progression at the early stage, and that overexpression of USP22 in tumor tissues could be used as a potential prognostic marker for patients with early clinical stage of NSCLC.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

J. Ning, The Third Affiliated Hospital of Harbin Medical University
Department of Thoracic Surgery
J. Zhang, The Third Affiliated Hospital of Harbin Medical University
Department of Thoracic Surgery
W. Liu, The Third Affiliated Hospital of Harbin Medical University
Fourth Department of Internal Medicine
Y. Lang, The Third Affiliated Hospital of Harbin Medical University
Department of Thoracic Surgery
Y. Xue, The Third Affiliated Hospital of Harbin Medical University
Department of Gastrointestinal Surgery
S. Xu, The Third Affiliated Hospital of Harbin Medical University
Department of Thoracic Surgery

How to Cite

Ning, J., Zhang, J., Liu, W., Lang, Y., Xue, Y., & Xu, S. (2012). Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer. European Journal of Histochemistry, 56(4), e46. https://doi.org/10.4081/ejh.2012.e46